Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : CDC guidance on masking unchanged as Delta variant sweeps U.S. - Walenksy

07/22/2021 | 01:01pm EDT

July 22 (Reuters) - The U.S. Centers for Disease Control and Prevention has not revised its masking guidance, even as the infectious Delta variant of COVID-19 continues to sweep the United States, driving up case counts, CDC director Rochelle Walensky said during a Thursday press call.

Walensky declined to say if the CDC is considering changing the guidance. The CDC in May relaxed its guidance so that fully vaccinated people do not need to wear masks in most public spaces.

Her comments come a day after U.S President Joe Biden said that the CDC is likely to advise unvaccinated children to wear masks in school as districts around the country prepare to reopen for the coming school year.

The seven-day average of new cases in the United States is up 53% over the previous week, Walensky said. The Delta variant, which was first found in India, now comprises more than 80% of new cases nationwide and has been detected in more than 90 countries.

Some hospitals around the United States are reaching their capacity limits as cases of COVID-19 continue to surge, Walensky said on the call.

The uptick in cases is concentrated in regions of the United States with lower vaccination rates. Florida, Texas and Missouri account for 40% of all new cases nationwide, with around 1 in 5 of all new U.S. cases occurring in Florida, White House COVID-19 task for director Jeffrey Zients said.

Zients said that the United States will continue to distribute tens of millions of COVID-19 vaccines around the world.

The White House in June announced plans to distribute around 80 million COVID-19 vaccines globally.

Top U.S. infectious disease expert Anthony Fauci said there is no reason for people who received Johnson & Johnson's COVID-19 vaccine to assume that they need to get an additional shot of Pfizer Inc's or Moderna Inc's vaccines to protect themselves against new variants.

The CDC and U.S. Food and Drug Administration are reviewing data to see if there is waning immunity in vaccinated people to determine if additional booster shots are needed. (Reporting by Carl O'Donnell in New York and Jeff Mason and Lisa Lambert in Washington D.C., Editing by Franklin Paul and Marguerita Choy)

ę Reuters 2021
All news about MODERNA, INC.
05:26pMODERNA : U.S. CDC Says 212,564,346 Individuals Have Received At Least One Dose Of Covid-1..
12:12pMODERNA : EU drugs regulator to decide on Pfizer vaccine booster in early October
12:01pGLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
11:06aASTRAZENECA : Vaccination Against Covid-19 Resumes Sept 24
05:51aMODERNA : EU regulator to decide on Pfizer booster at the start of October - source
04:41aMODERNA : COVID-19 Pandemic Could Be Over Within One Year, Moderna CEO Says
03:49aModerna chief executive sees pandemic over in a year - newspaper
02:21aASTRAZENECA : invests in Imperial's self-amplifying RNA technology with eye on future drug..
01:29aMODERNA : REFILE-Moderna chief executive sees pandemic over in a year - newspaper
09/22ASTRAZENECA : Japan doubles COVID-19 vaccine donation pledge to 60 mln doses
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 15,3x
Yield 2021 -
Capitalization 183 B 183 B -
EV / Sales 2021 8,38x
EV / Sales 2022 7,78x
Nbr of Employees 1 300
Free-Float 90,3%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 16
Last Close Price 454,60 $
Average target price 306,23 $
Spread / Average Target -32,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.335.15%177 895
LONZA GROUP AG33.16%61 006
CELLTRION, INC.-20.75%31 824
SEAGEN INC.-3.41%30 776